Kura Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KURA research report →
About the company
Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
- CEO
- Troy Wilson
- IPO
- 2015
- Employees
- 260
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $985.40M
- P/E
- -3.31
- P/S
- 13.76
- P/B
- 9.12
- EV/EBITDA
- -3.32
- Div Yield
- 0.00%
- Gross Margin
- 94.66%
- Op Margin
- -443.54%
- Net Margin
- -411.19%
- ROE
- -141.95%
- ROIC
- -57.53%
- Revenue
- $67.48M · 25.24%
- Net Income
- $-278,666,000 · -60.17%
- EPS
- $-3.18 · -57.43%
- Op Income
- $-303,631,000
- FCF YoY
- -152.82%
- 52W High
- $12.49
- 52W Low
- $5.45
- 50D MA
- $9.63
- 200D MA
- $9.48
- Beta
- 0.35
- Avg Volume
- 1.70M
Get TickerSpark's AI analysis on KURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Leoni Mollie | sell | 84,929 |
| Jun 4, 26 | Parks Diane L. | other | 35,000 |
| Jun 4, 26 | VASCONCELLES MICHAEL | other | 35,000 |
| Jun 4, 26 | Hasnain Faheem | other | 35,000 |
| Jun 4, 26 | Collins Helen Louise | other | 35,000 |
| Jun 4, 26 | SCHAFER CAROL | other | 35,000 |
| Jun 4, 26 | Szela Mary T | other | 35,000 |
| Jun 4, 26 | Malley Thomas | other | 35,000 |
| May 21, 26 | Powl Brian T. | sell | 10,000 |
| May 19, 26 | Powl Brian T. | sell | 339 |
Our KURA coverage
Recent articles, reports, and earnings notes.
No research on KURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KURA report →Similar companies
Peers in the same neighborhood.